… Denton has received honoraria and consultancy fees from Actelion, BioVitrum, Encysive,
Pfizer, and Genzyme Therapeutics, and research funding from Actelion, Aspreva …

… Conflict of interest: CP Denton reports grants and personal fees from Actelion and Roche,
grants from GSK, and personal fees from Bayer and Boehringer Ingelheim, during the conduct …

Systemic sclerosis, also called scleroderma, is an immune-mediated rheumatic disease that
is characterised by fibrosis of the skin and internal organs and vasculopathy. Although …

Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Objective Recurrent digital ulcers are a manifestation of vascular disease in patients with
systemic sclerosis (SSc; scleroderma) and lead to pain, impaired function, and tissue loss. We …

Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic
sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung …

Background: Systemic sclerosis (SSc) is a multisystem autoimmune disease, which is classified
into a diffuse cutaneous (dcSSc) and a limited cutaneous (lcSSc) subset according to the …

… Professor Denton has served on the advisory board of and received speaking fees (less
than $10,000) from Actelion Pharmaceuticals. Professor Black has received consulting fees (…

Rationale: In interstitial lung disease complicating systemic sclerosis (SSc-ILD), the optimal
prognostic use of baseline pulmonary function tests (PFTs) and high-resolution computed …

Objective: To determine the prevalence of systemic sclerosis associated pulmonary arterial
hypertension (SScPAH), evaluate outcome, and identify predictors of mortality in a large …